2018 Oral Mucositis Drug Development - Pipeline Analysis - ResearchAndMarkets.com

July 12, 2018

DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “2018 Oral Mucositis Drug Development- Pipeline Analysis Report” report has been added to ResearchAndMarkets.com’s offering.

With an estimated $2 billion market value, the Oral Mucositis disease pipeline presents strong opportunities for development of treatment options. Absence of preventive or curative treatment for the Oral Mucositis is encouraging investigators in major companies to focus on pipeline. Further, an increasing trend towards grant announcements is being observed in the segment.

The disease occurs primarily as a result of damage to epithelium by chemoradiation.

The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Oral Mucositis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Oral Mucositis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Key Topics Covered:

1 Oral Mucositis Pipeline Analysis

2 Oral Mucositis - Company Wise Pipeline Analysis

3 Oral Mucositis R&D Pipeline Snapshots

4 Recent Developments in Oral Mucositis Pipeline

5 Appendix

Companies Featured

ActoGeniX Anthera Pharmaceuticals Inc AstraZeneca Plc BIOCND Cilian AG Clevexel Pharma Colby Pharmaceutical Company Daewoong Pharmaceutical Enzychem Lifesciences Corporation Galera Therapeutics Genekey Biotech Chengdu Co Ltd GlycoMira Therapeutics Humanetics Corporation Hyloris Pharmaceuticals INCResearch Australia Pty Ltd Innovation Pharmaceuticals Intrexon Izun Pharmaceuticals Corporation Laboratoires Mayoly Spindler SAS Monopar Therapeutics Mundipharma International Ltd Nordmark Arzneimittel GmbH & Co KG Novartis Pharmaceuticals Onxeo S.A. Oragenics PolyMedix SRI International Santalis Pharmaceuticals SciClone Pharmaceuticals, Inc. Servier Canada Inc Soligenix In Spectrum Pharmaceuticals Spherium Biomed S.L. Sunny Pharmtech Wellstat Therapeutics Corporation

For more information about this report visit https://www.researchandmarkets.com/research/69j9kb/2018_oral?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005463/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Gastrointestinal Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/12/2018 09:05 AM/DISC: 07/12/2018 09:06 AM


Update hourly